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IGF-binding proteins (IGFBPs) and their proteases regulate IGFs bioavailability in multiple tissues. Pregnancy-associated plasma
protein A (PAPP-A) is a protease acting by cleaving IGFBP2, 4, and 5, regulating local bioavailability of IGFs. We have previously
shown that IGFs and IGFBPs are produced by human adult cardiac progenitor cells (haCPCs) and that IGF-1 exerts paracrine
therapeutic effects in cardiac cell therapy with CPCs. Using immunofluorescence and enzyme immunoassays, we firstly report that
PAPP-A is produced and secreted in surprisingly high amounts by haCPCs. In particular, the homodimeric, enzymatically active,
PAPP-A is secreted in relevant concentrations in haCPC-conditioned media, while the enzymatically inactive PAPPA/proMBP
complex is not detectable in the same media. Furthermore, we show that both homodimeric PAPP-A and proMBP can be detected
as cell associated, suggesting that the previously described complex formation at the cell surface does not occur easily, thus positively
affecting IGF signalling. Therefore, our results strongly support the importance of PAPP-A for the IGFs/IGFBPs/PAPP-A axis in
CPCs biology.
1. Introduction
IGFs, IGF receptors, and IGF-binding proteins (IGFBPs) are
expressed in the heart, being involved in tissue homeostasis,
and their levels change locally following infarction [1], par-
ticipating in postischaemic neovascularization and stimulat-
ing the reentry of adult ventricular myocytes into the cell
cycle [2]. Interaction of IGF-1 with its receptor stimulates
DNA and protein synthesis and contractility and inhibits
apoptosis in cardiomyocytes. IGF-1 is also robustly released
by heart-biopsy-derived cardiac progenitors cells (CPCs)
cultured ex vivo as cardiospheres (CSps) [3] and CSp-
derived cells (CDCs) [4], contributing to their autocrine
and paracrine function [5] in cardiac regenerative medicine
approaches [6, 7] of cell therapy [8] and tissue engineering
[9, 10]. Furthermore, IGF-1 is produced by cardiac fibroblasts
[11] and has a regulatory role in the stem cell niche [12].
At tissue level, IGFBP proteases control IGFs availability,
and they are individually regulated by specific inhibitors.The
most fully characterized is the pregnancy-associated plasma
proteinA (PAPP-A) system for cleaving IGFBPs. IGFBPs bind
IGFs with similar or higher affinities than IGF-receptors,
regulating their biological activities by acting as a reservoir
of IGFs in the circulation and by modulating the interactions
between IGFs and their receptors at cellular level. PAPP-A
exerts a specific proteolytic activity on IGFBP-4 [13], IGFBP-
5 [14], and IGFBP-2 [15], thus directly contributing to the
extent of IGF-dependent cellular effects. The widespread
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distribution of PAPP-A has been also associated with tissue
regeneration mechanisms by releasing IGFs that are capable
of activating macrophages, stimulating fibroblasts prolifera-
tion and matrix protein biosynthesis [16].
PAPP-A is mainly produced not only by the trophoblast
during pregnancy (low levels in the first trimester are asso-
ciated with chromosomal abnormalities [17] and pregnancy-
induced hypertension [18]), but also by granulose cells,
fibroblasts, osteoblasts, and endothelial and vascular smooth
muscle cells [19]. Circulating PAPP-A in pregnancy predom-
inantly exists as a heterotetramer, complexed in a 2 : 2 ratio
with its inhibitor, the proform of eosinophil major basic
protein (proMBP) [20], and denoted as PAPP-A/proMBP.
Elevated serum levels of the active homodimeric PAPP-
A (dPAPP-A) have also been found in patients with acute
coronary syndrome (ACS). In these cases, pathogenic mech-
anisms might be due to the increase of local concentration
of PAPP-A which, following cleavage of IGFBPs, allows
the release and promotion of IGF-related proatherogenic
effects [21]. Indeed, it has been shown in vitro that IGF is
able to induce activation of inflammatory cells and release
of inflammatory cytokines by activated macrophages, thus
promoting plaque progression and destabilization [21, 22].
Further observations on the role of PAPP-A as mediator of
cardiovascular diseases include the association of its serum
levels with the severity of heart failure and with the risk
for adverse cardiac events [23]. PAPP-A is also emerging
as a promising prognostic marker in patients with stable
cardiovascular disease [24] and ST-elevation myocardial
infarction [25].
On the other hand, cardiovascular protective effects of
IGF activity have been previously described and include
protection against endothelial dysfunction, athererosclerotic
plaque development, metabolic syndrome, and ischemic
myocardial damage. Interestingly, IGF-1 contributes to endo-
thelial and parenchymal regeneration at the site of tissue
damage by expanding the pool of progenitor cells [26].
However, the involvement of PAPP-A in this dynamic system
has not been reported and the present study was undertaken
to assess the presence and release of PAPP-A by humanCPCs,
stressing its potential importance on IGFBP modulation and
IGF release.
To investigate the balance and regulation of the IGFs/
IGFBPs/PAPP-A network in CPCs biology, we assessed
the expression and release of PAPP-A forms by CSps and
CDCs, using immunological and enzymatic assays specifi-
cally detecting dPAPP-A, proMBP, and the PAPP-A/proMBP
complex.
2. Materials and Methods
2.1. Cell Culture. CPCs were isolated and cultured by the CSp
method, as previously described [3, 28], from surgical human
auricola biopsies, during clinically indicated procedures after
informed consent in an institutional review board-approved
protocol, conforming with the principles of the Declaration
of Helsinki. Briefly, CSps were cultured on poly-D-lysine (BD
Biosciences) coated plates at 104 cells/cm2 in CSp-growth
medium (CGM): 35% IMDM and 65% DMEM/F-12 Mix,
3.5% FBS (Hyclone), 1% penicillin-streptomycin, 1% L-gluta-
mine, 0.1mmol/L 2-mercaptoethanol, 1 unit/mL thrombin
(Sigma), 1 : 50 B-27 (Invitrogen), 80 ng/mL bFGF, 25 ng/mL
EGF, and 4 ng/mL cardiotrophin-1 (Peprotech). CDCs were
grown on fibronectin (Sigma) coated flasks at 2–4 × 104
cells/cm2 in 20% FBS complete explant medium (CEM):
IMDM, 1% penicillin-streptomycin, 1% L-glutamine, and
0.1mM 2-mercaptoethanol. Conditioned media (CMs) were
collected after 96 hours.
2.2. Antibodies for Immunocytochemistry (ICC) and Enzyme
Immunoassay (EIA). The following mouse monoclonal anti-
bodies were used for ICC and EIA: antihuman dPAPP-A
(4PD4-PAPP2, Hytest, referred to as 4PD4) and antihu-
man pro-MBP (5H9, Hytest). The following immunoglob-
ulin preparations from antisera were used: rabbit anti-
human PAPP-A (A0230, Dako) previously absorbed in a
negative affinity chromatography step over an immobilized
preparation of pregnancy-specific beta-1-glycoprotein (SP1),
obtained as previously described [29]. This latter antibody
reacts with both PAPP-A subunits and proMBP and therefore
is able to recognize dPAPP-A, PAPP-A/proMBP, and free and
complexed proMBP. Alexa Fluor 568 and Alexa Fluor 488
conjugated anti-mouse IgG and anti-rabbit IgG (Invitrogen)
were used as secondary antibodies for ICC. Capture antibody
used for EIAs was HRP conjugated rabbit antihuman PAPP-
A (P0042, Dako). This has been prepared by conjugation of
HRP to A0230 immunoglobulins and therefore has the same
specificity.
2.3. Immunofluorescence. Confocal microscopy analysis
(TCS DMIRE 2 Leica microscope, equipped with LCS Lite
Software; Leica) was performed after incubating freshly fixed
CSps and CDCs (4% paraformaldehyde, then permeabilized
with 0.2% Triton X-100) with primary and secondary
antibodies listed previously. Nuclei were stained by Topro3
nuclear dye (Invitrogen) [3]. Appropriate negative controls
for autofluorescence and aspecific recognition by secondary
antibodies have been performed during all staining protocols.
Additionally, positive controls for all primary antibodies
have been performed on human trophoblast preparations, as
described in [27].
2.4. Sample Preparation andHeparin-Sepharose Affinity Chro-
matography. CMs from CSps (𝑛 = 20) and from CDCs
(𝑛 = 20) were separately pooled and assayed by time-resolved
immunofluorometric assay (TRIFA) before diafiltration on
X-100A nonionic membranes (Diaflo, 43mm diameter, Ami-
con) using a stirred cell (Model 52, Amicon); these CMs
were finally concentrated to small volumes with 0.02M Tris
buffer solution, pH 7.2, 0.15MNaCl. Affinity chromatography
of concentrated CMs through Heparin-Sepharose (CL-6B,
GE Healthcare) was performed as previously described [27].
Solutions containing 10U of PAPP-A were applied to 1 ×
6 cm column filled with the solid phase and equilibrated with
the same Tris buffer solutions, and they allowed recycling
at a flow rate of 25mL/hour for 1 hour. One mL fractions
were eluted with equilibrating buffer, followed by stepwise
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increase of NaCl concentration from 0.3M to 0.9M NaCl.
Fractions were pooled on the basis of their absorbance at
278 nm and submitted to time-resolved immunofluorometric
assay (TRIFA).
2.5. Immunofluorometric and Enzyme Immunoassays (EIA).
PAPP-A concentrations were measured in individual CSp-
and CDC-CMs, in pools of CSp-CMs and pools of CDC-
CMs and in their fractions, obtained from Heparin Sepha-
rose chromatography, by TRIFA (DELFIA Xpress 6000,
PerkinElmer), which recognizes dPAPP-A and PAPP-A/
proMBP. Fluorescence of Europium at 615 nm was the
endpoint of the automated assay, which uses pooled third
trimester pregnancy serum-derived pregnancy-associated
proteins WHO 78/610 reference preparation [30] as a Stan-
dard (WHO International Laboratory for Biological stan-
dards, Statens Serum Institute, Copenhagen, Denmark).
Assay sensitivity was 5mU/L.
PAPP-A concentrationswere also assessed by direct sand-
wich EIAs on 96-well plates (Nunc-Immuno Plate) based on
three different capture antibodies: (a) 4PD4 (0.14 𝜇g/100 𝜇L),
(b) A0230 (0.1 𝜇g/100 𝜇L), and (c) 5H9 (0.09 𝜇g/100 𝜇L).
Antibodies, diluted in PBS, were used for coating, which was
performed at 4–8∘C for 12–18 hours.Wells were washed three
times with PBS and nonspecific adsorption sites were blocked
for 1 hour by 250𝜇L of Casein Blocking Buffer (Thermo
Scientific) at room temperature. After washing, 75𝜇L sample
and 25 𝜇L of fetal calf serum, or their dilutions in Blocking
Buffer, were added to the wells and plates incubated for 18–
24 hours at 4–8∘C. After three washes, the same detection
antibody (P0042, 1 : 400 in the same buffer solution) was
added to the three immunoassays, and incubation continued
at 37∘C for 1 hour. After five more washes with 250𝜇L
blocking buffer, colour was developed by allowing 100 𝜇L
of tetramethyl benzidine (ImmunoPure TMB substrate kit,
Thermo Scientific) to react with HRP for 15 minutes at room
temperature. Reaction was stopped with 100 𝜇L of 1MH
2
SO
4
and absorbance was measured at 450 nm. The combinations
of the three capture antibodies with P0042 for detection were
intended to assay dPAPP-A, dPAPP-A and PAPP-A/proMBP,
and PAPP-A/proMBP, respectively.
The two pools of CMs, previously calibrated by TRIFA
against WHO 78/610 RP, were individually tested at different
dilutions by the three EIAs available. Serial dilutions of the
same WHO RP were also used as positive controls in the
A0230- and 5H9-based EIAs or negative controls in the
4PD4-based EIA. Sensitivities of the EIAs were 20mU/L (for
4PD4), 5mU/L (for A0230), and 40mU/L (5H9).
2.6. Statistical Analysis. Data are presented as mean value ±
standard error of the mean. Significance of difference
between any two groups was determined by two-sided Stu-
dents 𝑡-test, and a final value of 𝑃 < 0.05 was considered
significant.
3. Results
PAPP-A concentrations were initially assessed on indi-
vidual CMs (𝑛 = 40) by TRIFA, which recognizes both
CSps CDCs
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Figure 1: Quantification of PAPP-A secretion in CSps and CDCs
conditioned media. PAPP-A concentrations were measured by
immunofluorometric assay in individual 96-hour incubation CMs,
randomly selected for CSps (𝑛 = 6) and CDCs (𝑛 = 5),
and normalised to the total DNA content of the culture. PAPP-
A normalised levels were significantly higher in CSp-CMs than in
CDC-CMs (𝑃 = 0.018).
homodimeric PAPP-A and PAPPA/proMBP complex. Inter-
estingly, the obtained concentrations were biologically signif-
icant, being in the same order ofmagnitude of those routinely
measured by the clinical laboratory of our university in
maternal sera screened for Down’s syndrome risk at 9–12
weeks of pregnancy (400–1900mIU/L) and much higher
than those present in plasma of patients with myocardial
infarction (9.2–46.6mIU/L) [21]. When separately pooled,
CSp-CMs and CDC-CMs contained 810mU/L 78/610 RP
(range 220–1280mU/L) and 1510mU/L 78/610 RP (range
390–3010mU/L) of PAPP-A, respectively. However, when
normalized to the total DNA content of the culture, PAPP-
A levels were significantly higher in CSp-CM versus CDC-
CM, as shown in Figure 1. The presence of PAPP-A in pools
of CSp-CMs and pools of CDC-CMs has been firstly assessed
by affinity chromatography on heparin-sepharose column, a
procedure known for its selectivity in recognizing PAPP-A
and previously used for PAPP-A/proMBP separation from
normal term maternal serum [25, 26, 31]. In these experi-
ments more than 80% of the immunoassayable PAPP-A was
eluted with 0.6M NaCl, thus exhibiting a chromatography
behavior similar to that shown by the proMBP-complexed
enzyme. Recognition of dPAPP-A by Heparin was expected,
since the binding of the enzyme to a similar cell surface
glycosaminoglycan represents the prerequisite for addressing
its proteolytic activity on the cell surface [30].
Characterization of secreted PAPP-A in CMs was per-
formed by EIA using capture antibodies of different speci-
ficity but with the same HRP-conjugated capture antibody.
As shown in Figure 2, the monoclonal antibody specific
for dPAPP-A (4PD4) was able to recognize the antigen in
CMs from both CSps (Figure 2(a)) and CDCs (Figure 2(b)).
The antibody reacting with dPAPP-A and PAPP-A/proMBP
(A0230) also exhibited immunoreactivity for the two CMs.
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Figure 2: Immunoassayable PAPP-A using antibodies with different specificity. Titration of PAPP-A concentrations from CSp-CM (a) and
CDC-CM (b) by three different EIAs. A0230 antibody (recognizing both dPAPP-A and PAPP-A/proMBP), 4PD4 antibody (specific for
dPAPP-A), and 5H9 antibody (specific for the proMBP moiety) were used as capture antibodies for both CMs. In all cases, P0042 polyclonal
antibody (HRP—conjugated anti-PAPP-A) was used for detection. The anti-proMBP/anti-PAPP-A antibody combination failed to recognize
PAPP-A/proMBP complex in both CMs, whereas it was previously shown to be reactive with the pooled third trimester pregnancy serum-
derived WHO 78/610 RP and with first and third trimester pregnancy human placental extracts [27].
By contrast, the proMBP subunit-specific antibody (5H9,
used in combination with HRP-conjugated PAPP-A poly-
clonal antibody P0042) failed to react with the same media.
On the other hand, capacity of the same antibody combi-
nation (5H9 and P0042) of reacting with PAPP-A/proMBP,
present in pregnancy sera or placenta extracts, has been
previously demonstrated [27] and confirmed by its ability of
reacting with the WHO 78/610 RP at PAPP-A concentrations
as low as 40 mU/L. Taken together, these results indicate that
only active dPAPP-A and not PAPP-A/proMBP is secreted in
both CSp-CM and CDC-CM.
Immunofluorescence confocal analyses revealed that
staining patterns obtained with the antibody against both
dPAPP-A andPAPP-A/proMBP (A0230) partially overlapped
with those of anti-dPAPP-A antibody (4PD4), suggesting a
large extent of recognition of the same epitope (Figures 3(a)
and 3(b)).
Immunocytochemical control stainings on human pla-
cental trophoblast preparations revealed the ability of all
primary antibodies (A0230, 4PD4, 5H9) to detect PAPP-A,
confirming their specificity (data not shown). Furthermore,
negative controls showed no unspecific fluorescence of our
secondary antibodies (data not shown). Based on these
results, the uncomplete overlapping of the two antibodies
A0230 and 4PD4 might be due to the different accessibility
of their specific epitopes.
However, as evidenced by confocal images acquired at
different focus planes, in 3D CSps, the homodimeric active
PAPP-A seemed preferentially associated with outer cell
layers (Figure 3(b)), usually housing the more differentiated
cells [3, 32], consistently with the model of the CSp as
an in vitro niche-like structure of spatially regulated gene
expression and functions [6, 32, 33]. In a similar manner,
the overlapped stainings of A0230 and 5H9 could be due to
cross-reactivity of the first with proMBP (Figures 3(c) and
3(d)).WhenCDCswere stainedwith 4PD4 antibody, dPAPP-
A appeared localized near the membrane and superimposed,
at least in part, to the staining given by A0230 (Figure 3(e)).
The presence of proMBP within CSps and CDCs was proven
by the positive patterns shown by 5H9 antibody (Figures 3(d)
and 3(f)). The same patterns did not allow distinguishing
the free from the complexed proMBP, given the specificity
of the antibody used for the subunit of proMBP. Direct
immunocytochemical lines of evidence of the PAPP-A com-
plex formation on the cell surface could not be obtained, since
an antibody specific for the complex is not available.
4. Discussion
IGF1 and the regulation of its availability play important
roles in cardiac pathophysiology [34]. PAPP-A is one of the
better characterized systems for the control of IGF1/IGFBPs
binding and the consequent modulation of IGF1 bioavail-
ability and activity. In this study, we detected significant
amounts of secreted active PAPP-A in CPC-CMs. In particu-
lar, CSps secreted higher PAPP-A concentrations than CDCs
in their respective CMs (Figure 1). CSps have a characteristic
three-dimensional structure representing an in vitro niche-
like microenvironment. This distinctive 3D conformation
improves the paracrine potential of CSps versus CDCs, as
previously described [5]. Given that it has been already
shown that CSps produce higher levels of IGF1 and IGFBPs
compared to CDCs [5, 32], we can speculate that the higher
production of PAPP-A could be necessary for the dynamic
regulation of the IGF axis, supporting the notion of an impor-
tant role for the IGF1-network in CPC biology. Interestingly,
our immunoassays show that only the active homodimeric
PAPP-A form is secreted by CSps and CDCs (Figure 2).
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Figure 3: Immunofluorescence and confocal analysis of PAPP-A in CSps and CDCs. Representative confocal images for the detection
of PAPP-A in CSps (a–d) and CDCs (e-f) by immunofluorescence: PAPP-A/proMBP complex and free PAPP-A are stained by A0230;
homodimeric PAPP-A is recognized by 4PD4 antibody and pro-MBP by 5H9. Note that (a–d) display different focal planes (core or surface)
of the same CSp, showing how the spatial distribution of dPAPP-A and proMBP, respectively, varies inside the 3D structure of the CSp. A
higher magnification panel of the corresponding evidenced area is shown as insert in (e).
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The data from immunofluorescence analysis confirm the
intracellular presence of active dPAPP-A (Figure 3) and a
preferential distribution in the CSp external layers. This is
consistent with the notion of the CSp as a finely regulated
niche-like structure [6, 32, 33], where the activity and avail-
ability of regulatory proteins, such as IGF1, must be under
spatial and biological control. This is also consistent with the
evidence of the binding capacity of the newly synthesized
PAPP-A on the cell surface, where it posttranslationally
modulates IGFBPs by limited proteolysis [30].
However, we were unable to ascertain the presence of
PAPP-A/proMBP complex on the cell surface by immunoflu-
orescence confocal microscopy. This failure could be due to
the lack of specificity of the primary antibodies used for
targeting the complex only, since A0230 antibody recognized
epitopes present in the PAPP-A subunit and in the proMBP
subunit, while 5H9 antibody is not able to distinguish free
from bound proMBP. Lack of identification of the PAPP-
A/proMBP complex might be due also to the high rate of
formation and detachment of the complex from the cell
surface, to its very weak capacity of surface binding [35], or
to a substantial change in the balance between complexed
and uncomplexed PAPP-A. Failure of the proMBP/PAPP-A-
based sandwich immunoassay to detect the complex secreted
into the CMs, together with the assessment of the expression
of proMBP by cells, seems to support the last hypothesis.
Perhaps, the multistep procedure of the complex formation
involving a disulphide interchange between the two proteins
might be altered in our experimental conditions. A number
of experimental procedures are known to be able to affect the
dynamics of the postsynthetic interaction of proMBP with
its target proteins at the cell surface. They include regulatory
mechanisms as redox potential, presence of reductase,metals,
sulfhydryl compounds, and mutations of cysteine residues
in proMBP, involved in the reduction and formation of
disulphide bonds participating in the complex formation
[36]. Failure of proMBP to complex with PAPP-A might
represent a cellular strategy to control IGFs activity. Indeed,
recently it has been demonstrated that disulphide cleavage in
the extracellular domains of cell surface receptors, as well as
in secreted soluble proteins, may be considered a switch for
protein function [37].
The specificity of the monoclonal antibody 4PD4 used in
this study to detect dPAPP-A has been previously tested by
other authors using sandwich immunoassay [38]. Its capacity
to recognize dPAPP-A without cross-reactivity with PAPP-
A/proMBP complex is confirmed in our study, by using
it as the capture antibody in combination with the HRP-
conjugated anti-PAPP-A immunoglobulin as the detection
antibody. Since this enzymatic immunoassay was unable to
react with a pool of term pregnancy sera and with the WHO
78/610 RP, probably the sensitivity of the assay (20mU/L)
did not allow the detection of the small fraction of dPAPP-
A (less than 1%) at the concentration tested, whereas the
same antibodywas able to recognize dPAPP-A in conditioned
media fromCDCs and CSps, allowing the clear identification
of the antigen as dPAPP-A.
In conclusion, we have firstly demonstrated that free
dimeric PAPP-A is expressed and released by CPCs in the
form of CSps and CDCs at biological and clinical physi-
ological relevant concentrations, being of the same order
of magnitude as the circulating level found in peripheral
blood of late first trimester pregnancy and ACS patients.
Given the crucial cardioprotective and prosurvival roles of
IGFs, both autocrine and paracrine, for the first time, our
data demonstrate the production of active dimeric PAPP-
A, besides IGFs and IGFBPs [5], by CSps and CDCs. It
can be consistently speculated that PAPP-A is part of the
IGFs network and that it participates in IGFs bioavailability
and bioactivity on CPCs and their microenvironment. Fur-
thermore, based on their potent PAPP-A secretory profile,
a possible contribution of CPCs to elevated PAPP-A serum
levels occurring in ACS could be speculated as a consequence
of spontaneous, albeit limited, activation of endogenous heart
regeneration in response to injury. Detection of PAPP-A
secreted by the cells into their culture media depends, at least
in part, on its molecular structure and it is dependent on
the specificity of those antibodies recognizing dimeric PAPP-
A, which can successfully be used for assaying this CPC-
derived protease. Finally, CPCs seem to represent a novel
highlyproductive source of dPAPP-A protein, which may be
used for analytical and biochemical purposes, such as assay
standards and/or antigen purification for specific antibodies
productions.
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